iBio
IBIO
36 hedge funds and large institutions have $990K invested in iBio in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 20 closing their positions.
1,570% more call options, than puts
Call options by funds: $167K | Put options by funds: $10K
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
1.03% more ownership
Funds ownership: 0.03% → 1.06% (+1%)
16% less funds holding
Funds holding: 43 → 36 (-7)
35% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 20
80% less capital invested
Capital invested by funds: $4.97M → $990K (-$3.98M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$830K |
| 2 |
Renaissance Technologies
New York
|
+$558K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$190K |
| 4 |
Two Sigma Investments
New York
|
+$90.4K |
| 5 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$84.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
-$142K |
| 2 |
Millennium Management
New York
|
-$44.8K |
| 3 |
N
Natixis
Paris,
France
|
-$33K |
| 4 |
Charles Schwab
San Francisco,
California
|
-$31K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$27K |
IBIO Hedge Fund Activity: Q4 2022 in Review
36 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in iBio (IBIO) for Q4 2022, worth a combined $990K — down 80% from $4.97M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of IBIO and 13 opened new positions — a net loss of 7 holders — while 5 trimmed existing stakes and 8 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $830K. The largest seller was Ergoteles, exiting entirely with an estimated $142K sold.
- 36 institutional investors held iBio (IBIO) as of Q4 2022, down from 43 in Q3 2022.
- Funds reported $990K of iBio stock for Q4 2022, down 80% quarter-over-quarter.
- 13 funds opened new iBio positions in Q4 2022 and 20 closed out, a net change of -7 holders.
- The largest iBio buyer in Q4 2022 was Sabby Management, an estimated $830K added.
- The largest iBio seller in Q4 2022 was Ergoteles, an estimated $142K sold.
Based on aggregated 13F filings for Q4 2022.